Host-Directed Therapeutics
Due: May 30, 2025 The JPEO-CBRND is interested in late-stage development of host-directed therapeutics or repurposing of United States Food and Drug Administration (FDA) licensed therapeutics that are threat-agnostic with the potential for activity across Read More